Month: March 2025

Niu Technologies Announces Unaudited Fourth Quarter and Full Year 2024 Financial Results

Written by Customer Service on March 17, 2025. Posted in Earnings Releases And Operating Results.

— Fourth Quarter Revenues of RMB 819.2 million, increase 71.1% year over year — Fourth Quarter Net Loss of RMB 72.5 million, compared to net loss of RMB 130.2 million in the same period of last year — Full Year Revenues of RMB 3,288.3 million, increase 24.0% year over year — Full Year Net loss of RMB 193.2 million, compared to net loss of RMB 271.8 million in 2023 BEIJING, March 17, 2025 (GLOBE NEWSWIRE) — Niu Technologies (“NIU”, or “the Company”) (NASDAQ: NIU), the world’s leading provider of smart urban mobility solutions, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial HighlightsRevenues were RMB 819.2 million, an increase of 71.1% year over year Gross margin was 12.4%, compared with 19.0% in the fourth quarter...

Final Results for the Year-Ended December 31, 2024

Written by Customer Service on March 17, 2025. Posted in Earnings Releases And Operating Results.

Diversified Achieves Strong Final Year-End 2024 Results, Delivers on Capital Allocation Promises, and Introduces 2025 Combined Company Outlook 2024 Achievements Position Diversified on a Meaningful Path Forward as a Stronger and Larger Company Executed Approximately $2 Billion of Acquisitions in an Advantageous Pricing Environment Third year of Consistent Operating Costs Despite Broader Industry and Inflationary Pressures Maverick Integration Anticipated to Provide Meaningful Financial and Operational Benefits to Drive Free Cash Flow Acceleration Created a PDP Solution for Upstream Peers to Facilitate Operated Acquisitions with an Undeveloped Inventory Focus BIRMINGHAM, Ala., March 17, 2025 (GLOBE NEWSWIRE) — Diversified Energy Company PLC (LSE: DEC; NYSE: DEC) is pleased to announce its operational and final audited results for...

Nexans enters into exclusive negotiations with Latour Capital for the sale of Lynxeo

Written by Customer Service on March 17, 2025. Posted in Mergers And Acquisitions.

Nexans enters into exclusive negotiations with Latour Capital for the sale of Lynxeo PRESS RELEASENexans announces having entered into exclusive negotiations with Latour Capital for the sale of Lynxeo for €525 million, subject to customary approvals With the proposed transaction, Nexans would achieve major step on its strategy to become a Pure Electrification PlayerParis, March 17th, 2025 – Nexans announces today having entered into exclusive negotiations for the sale of its industrial cable division Lynxeo to Latour Capital, a France-based private equity fund, for an Enterprise Value of €525 million. This proposed transaction would mark Nexans’ exit from the specialty industrial cables activity in line with its strategy to refocus as a Pure Electrification Player. Lynxeo is a powerhouse in specialty industrial cables and plays...

EsoBiotec to Be Acquired by AstraZeneca to Advance Cell Therapy Ambition

Written by Customer Service on March 17, 2025. Posted in Mergers And Acquisitions.

Acquisition includes EsoBiotec’s world-leading in vivo delivery platform with potential to transform cell therapy MONT-SAINT-GUIBERT, Belgium, March 17, 2025 (GLOBE NEWSWIRE) — EsoBiotec SA, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity, today announced it has entered into a definitive agreement to be acquired by AstraZeneca (LSE/STO/Nasdaq: AZN). The EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform empowers the immune system to attack cancers and could offer many more patients access to transformative cell therapy treatments delivered in just minutes rather than the current process which takes weeks. ENaBL uses highly targeted lentiviruses to deliver genetic instructions to specific immune cells, such as T cells, which programme them to recognise and...

Publication of the statement from the Board of Directors regarding Constantinsborg A/S’ voluntary cash offer to the shareholders of FirstFarms A/S

Written by Customer Service on March 17, 2025. Posted in Mergers And Acquisitions.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF ANY APPLICABLE LAWS OR REGULATIONS, INCLUDING IN THE UNITED STATES OF AMERICA Publication of the statement from the Board of Directors regarding Constantinsborg A/S’ voluntary cash offer to the shareholders of FirstFarms A/S With reference to company announcement no. 2/2025 and company announcement no. 10/2025 regarding Constantinsborg A/S’ (the “Offeror”) decision to submit a voluntary cash offer for all shares in FirstFarms A/S (“FirstFarms”) (excluding treasury shares held by FirstFarms and shares already held by the Offeror) at an offer price of DKK 84.00 per share with a nominal value of DKK 10 (the “Offer”) and publication of the offer document, FirstFarms hereby publishes the statement...

Bureau Veritas strengthens its leading position in the Chilean copper market through the acquisition of GeoAssay

Written by Customer Service on March 17, 2025. Posted in Mergers And Acquisitions.

PRESS RELEASE Paris – March 17, 2025 Bureau Veritas strengthens its leading position in the Chilean copper market through the acquisition of GeoAssay Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), announces the acquisition of GeoAssay. This transaction cements Bureau Veritas’ position as the Metals & Minerals market leader in Chile, the world’s largest copper producer. Bureau Veritas’ Metals & Minerals operations aim to support our clients throughout the entire mining cycle, from mine to port. This is achieved by accurately determining the physical, chemical and geochemical properties of materials through our extensive network of laboratories. With a global presence in major ports around the world and with global mining and refining locations, Bureau Veritas’ footprint is expanding...

Net asset value of the EfTEN United Property Fund as of 28.02.2025

Written by Customer Service on March 17, 2025. Posted in Public Companies.

The net asset value (NAV) per unit of EfTEN United Property Fund was 11,27 euros at the end of February, up 0,4% in the month. The fund earned 117 thousand euros in net profit in February and 525 thousand euros in net profit in the first two months of the year (113 thousand euros at the same time last year). In February, EfTEN United Property Fund’s profit was negatively affected by an investment in EfTEN Real Estate Fund AS shares, which closed on the stock exchange in February at 0,3% lower than at the end of the previous month. If the fund’s investment in EfTEN Real Estate Fund AS shares were recorded on the basis of its net asset value, EfTEN United Property Fund’s NAV would be 11,33 euros, up 0,5% in the month. The decline in EfTEN Real Estate Fund’s share price was primarily offset by the results of the EfTEN...

US FDA removes REMS requirement for TRYVIO (aprocitentan) – minimizing the burden on the healthcare delivery systems and patients

Written by Customer Service on March 17, 2025. Posted in Public Companies.

Ad hoc announcement pursuant to Art. 53 LRFDA confirms that prescribers and pharmacists are no longer expected to interact with the REMSAllschwil, Switzerland – March 17, 2025Idorsia Ltd (SIX: IDIA) today announced that – effective immediately – the US FDA has fully released TRYVIO™ (aprocitentan) from its REMS (Risk Evaluation and Mitigation Strategy) requirement. TRYVIO is Idorsia’s dual endothelin receptor antagonist (ERA) indicated for the treatment of systemic hypertension in combination with other antihypertensives to lower blood pressure in patients who are not adequately controlled on other drugs. The US FDA has determined that a REMS is no longer necessary to ensure the benefits of TRYVIO outweigh the risk of embryo-fetal toxicity and that labeling is sufficient for conveying the safety information. The FDA have therefore...

12/2025・Trifork Group: Weekly report on share buyback

Written by Customer Service on March 17, 2025. Posted in Public Companies.

Company announcement no. 12 / 2025Schindellegi, Switzerland – 17 March 2025 Trifork Group: Weekly report on share buyback On 28 Februay 2025, Trifork initiated a share buyback program in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buyback program runs from 4 March 2025 up to and including no later than 30 June 2025. The buyback program will not be active from 9 to 15 April 2025. For details, please see company announcement no. 7 of 28 February 2025. Under the share buyback program, Trifork will purchase shares for up to a total of DKK 14.92 million (approximately EUR 2 million). Prior to the launch of the share buyback, Trifork held 256,329 treasury shares, corresponding to 1.3% of the share...

Roche to share latest scientific advancements from its neuromuscular portfolio at Muscular Dystrophy Association (MDA) 2025 conference

Written by Customer Service on March 17, 2025. Posted in Public Companies.

New Evrysdi five-year data from the SUNFISH study showed continued stabilisation of motor function in a broad population of individuals with Types 2 or 3 spinal muscular atrophy (SMA) Late-breaking oral on Elevidys’ Embark two-year data and pooled analysis of Study 101, 102 and Endeavor, demonstrated clinically meaningful and statistically significant improvements across key measures of motor function in boys with Duchenne muscular dystrophy (DMD) Muscle pathology as measured by MRI continued to generally favour Elevidys across muscle groups in boys with Duchenne up to two yearsBasel, 17 March 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present new data at the Muscular Dystrophy Association (MDA) conference, 16-19 March, 2025, in Dallas, Texas, from its neuromuscular portfolio, including 12 oral and...

Month: March 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals